GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Encision Inc (OTCPK:ECIA) » Definitions » ROE %

Encision (Encision) ROE % : -36.27% (As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Encision ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Encision's annualized net income for the quarter that ended in Dec. 2023 was $-0.83 Mil. Encision's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $2.28 Mil. Therefore, Encision's annualized ROE % for the quarter that ended in Dec. 2023 was -36.27%.

The historical rank and industry rank for Encision's ROE % or its related term are showing as below:

ECIA' s ROE % Range Over the Past 10 Years
Min: -39.68   Med: -11.36   Max: 23.47
Current: -18.66

During the past 13 years, Encision's highest ROE % was 23.47%. The lowest was -39.68%. And the median was -11.36%.

ECIA's ROE % is ranked worse than
65.38% of 806 companies
in the Medical Devices & Instruments industry
Industry Median: -0.54 vs ECIA: -18.66

Encision ROE % Historical Data

The historical data trend for Encision's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Encision ROE % Chart

Encision Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.36 -8.73 23.47 -2.38 -12.36

Encision Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.31 -14.67 -23.04 -1.35 -36.27

Competitive Comparison of Encision's ROE %

For the Medical Instruments & Supplies subindustry, Encision's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Encision's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Encision's ROE % distribution charts can be found below:

* The bar in red indicates where Encision's ROE % falls into.



Encision ROE % Calculation

Encision's annualized ROE % for the fiscal year that ended in Mar. 2023 is calculated as

ROE %=Net Income (A: Mar. 2023 )/( (Total Stockholders Equity (A: Mar. 2022 )+Total Stockholders Equity (A: Mar. 2023 ))/ count )
=-0.324/( (2.746+2.495)/ 2 )
=-0.324/2.6205
=-12.36 %

Encision's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-0.828/( (2.373+2.193)/ 2 )
=-0.828/2.283
=-36.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Encision  (OTCPK:ECIA) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-0.828/2.283
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.828 / 6.328)*(6.328 / 4.488)*(4.488 / 2.283)
=Net Margin %*Asset Turnover*Equity Multiplier
=-13.08 %*1.41*1.9658
=ROA %*Equity Multiplier
=-18.44 %*1.9658
=-36.27 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-0.828/2.283
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-0.828 / -0.828) * (-0.828 / -0.756) * (-0.756 / 6.328) * (6.328 / 4.488) * (4.488 / 2.283)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.0952 * -11.95 % * 1.41 * 1.9658
=-36.27 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Encision ROE % Related Terms

Thank you for viewing the detailed overview of Encision's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Encision (Encision) Business Description

Traded in Other Exchanges
N/A
Address
6797 Winchester Circle, Boulder, CO, USA, 80301
Encision Inc is a medical device company. The company develops and markets technology that provides unprecedented outcomes and patient safety in minimally-invasive surgery. The company has established and developed AEM (Active Electrode Monitoring) technology and surgical instruments which provides surgeons with the desired tissue effects of cutting and coagulating tissue in laparoscopic procedures while preventing stray electrosurgical energy that can cause complications and even death. The segments of the company are Product and Service. Product designs develops, manufactures and markets patented surgical instruments. Service performs electrical engineering activities for external entities.
Executives
Robert H Fries director 800 FILLMORE ST, DENVER CO 80206
Peter D Geary officer: VP of Operations 6797 WINCHESTER CIRCLE, BOULDER CO 80301
Jason E Johnson officer: VP Sales 17752 WEDGEWOOD LANE, PRIOR LAKE MN 55372
Patrick R Dixon director 6797 WINCHESTER CIRCLE, BOULDER CO 80301
Gregory J. Trudel director, officer: CEO 5241 RIMROCK LANE, FORT COLLINS CO 80526
Brian J Jackman director 6797 WINCHESTER CIRCLE, SUITE 100, BOULDER CO 80301
Von Der Lippe Paul director 6797 WINCHESTER CIRCLE, BOULDER CO 80301
Denise Baker director 6797 WINCHESTER CIRCLE, BOULDER X1 80301
Vern D Kornelsen director, 10 percent owner 4605 S. DENICE DR, ENGLEWOOD CO 80111
Partners Lllp Cmed 10 percent owner
Patrick W Pace director 3701 SOARING EAGLE, AUSTIN TX 78746
Michael Biggs officer: VP Engineering 6797 WINCHESTER CIRCLE, BOULDER CO 80301
Brad Greathouse officer: VP RA/QA 6797 WINCHESTER CIRCLE, BOULDER CO 80301
Valerie Ray officer: VP of Operations 6797 WINCHESTER CIRCLE, BOULDER CO 80301
David W Newton director, officer: VP Technology 8099 NORTH 63RD STREET, LONGMONT CO 80503

Encision (Encision) Headlines

From GuruFocus

Encision Reports First Quarter Fiscal Year 2022 Results

By PRNewswire PRNewswire 08-09-2021

Encision Signs Supplier Agreement with Human Xtensions

By ACCESSWIRE ACCESSWIRE 02-28-2023

Encision Introduces Its AEM® 2X enTouch® Scissors

By PRNewswire PRNewswire 08-05-2020

Encision Receives PPP Financing

By PRNewswire PRNewswire 04-23-2020

Encision Reports First Quarter Fiscal Year 2020 Results

By PRNewswire PRNewswire 08-12-2019

Encision Signs Supply Agreement with Auris Health, Inc.

By PRNewswire PRNewswire 08-24-2021

Encision Completes Private Placement of Common Stock

By PRNewswire PRNewswire 12-20-2018

Encision Reports Fourth Quarter Fiscal Year 2020 Results

By PRNewswire PRNewswire 05-14-2020